Biovest Names Lymphoma Key Opinion Leader from MD Anderson Cancer Center to Scientific Advisory Board

Biovest Names Lymphoma Key Opinion Leader from MD Anderson Cancer Center to Scientific Advisory Board

Biovest International, Inc.

Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that it appointed Sattva S. Neelapu, M.D., Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center to Biovest’s Scientific Advisory Board.

Earlier this year, Dr. Neelapu presented on , Biovest’s personalized cancer vaccine for the treatment of non-Hodgkin’s lymphoma, at a number of meetings with European national medicine agencies that led to Biovest’s decision to seek marketing approval in Europe. Supported via a grant awarded by the National Institutes of Health (NIH), Dr. Neelapu is also conducting additional analysis from the Phase III clinical trial. With a specialized focus on tumor immunology and cancer vaccines, Dr. Neelapu is the recipient of numerous awards from the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR) and U.S. National Cancer Institute (NCI).

In other news, Biovest announced that it will recognize the importance of World Lymphoma Awareness Day on September 15th by presenting and exhibiting at a patient/caregiver educational symposium in Chicago titled, “Follicular Lymphoma: On the Road to a Cure”. On the agenda, Stephen J. Schuster, M.D. is scheduled to discuss the emerging role of cancer vaccines to improve outcomes in the treatment of lymphoma. Dr. Schuster serves as the Robert and Margarita Louis-Dreyfus Associate Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research and Director of the Lymphoma Program at the Abramson Cancer Center of the University of Pennsylvania. He also serves on Biovest’s Scientific Advisory Board and has been instrumental in the clinical development of , presenting vaccine trial results at major peer-review cancer meetings including at the American Society of Clinical Oncology (ASCO) and at the American Society of Hematology (ASH).

For more information on the “Road to a Cure” lymphoma event, please visit:

Biovest’s President & CEO, Samuel S. Duffey, stated, “With the addition of Dr. Neelapu, we continue to assemble a world-class Scientific Advisory Board. To have such an accomplished group of key opinion leaders contributing to the advancement of is a testament to the science and potential of our personalized cancer vaccine technology and reflects a commitment to improve treatment outcomes for lymphoma patients.”

Biovest also reported that a multi-part series of articles are being published on the website, , highlighting the promise of personalized cancer vaccine for the treatment of non-Hodgkin’s lymphoma. The articles can be accessed in the Media Center at Biovest’s corporate website at:

Biovest International, Inc. develops active immunotherapies (cancer vaccines) which treat and diminish the aggressiveness of B-cell non-Hodgkin’s lymphoma, a cancer of the immune system. The Company’s lead personalized cancer vaccine product candidate, has been evaluated in three clinical trials conducted in collaboration with the U.S. National Cancer Institute (NCI) demonstrating that increases the duration of cancer remission following chemotherapy and induces immune responses which correlate highly with long-term survival. Biovest is currently in the process of pursuing European and Canadian marketing approvals for .

Headquartered in Tampa, Florida with its bio-manufacturing facility based in Minneapolis, Minnesota, Biovest is publicly-traded on the OTCQB™ Market with the stock-ticker symbol “BVTI”, and is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI).

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.